HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02

NCT02525302 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Dosing stopped

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG: HT-100

Sponsor

Akashi Therapeutics